d . 2009, 114 abstr 3078. 96. Santo L, Hideshima T, Nelson EA, et al. AT9283, a small molecule multi targeted kinase inhibitor induces antimyeloma activity via potent aurora kinase and STAT3 inhibition. Blood . 2009, TGX-221 114 abstr 3833. 97. Ravandi F, Foran J, Verstovsek S, et al. A phase I trial of AT9283, a multitargeted kinase inhibitor, in patients with refractory hematological malignancies. Blood . 2007, 110 abstr 904. 98. Foran JM, Ravandi F, O,Brien SM, et al. Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia. J Clin Oncol. 2008, 26 abstr 2518. 99. Plummer ER, Calvert H, Arkenau H, et al. A dose escalation and pharmacodynamic study of AT9283 in patients with refractory solid tumours. J Clin Oncol. 2008, 26 abstr 2519. 100.
Kristeleit R, Calvert H, Arkenau H, et al. A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors. J Clin Oncol. 2009, 27 abstr 2566. 101. Jani JP, Arcari J, Bernardo V, et al. PF 03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. XL880 Mol Cancer Ther. 2010, 9:883 94. 102. Jones SF, Burris HA III, Dumez H, et al. Phase I accelerated dose escalation, pharmacokinetic and pharmacodynamic study of PF 03814735, an oral aurora kinase inhibitor, in patients with advance solid tumors: preliminary results. J Clin Oncol. 2008, 26 abstr 2517. 103. Bebbington D, Binch H, Charrier J D, et al. The discovery of the potent aurora inhibitor MK 0457 . Bioorg Med Chem Lett. 2009, 19:3586 92. 104. Lin YG, Immaneni A, Merritt WM, et al.
Targeting aurora kinase with MK 0457 inhibits ovarian cancer growth. Clin Cancer Res. 2008, 14:5437 446. 105. Li Y, Zhang Z F, Chen J, et al. VX680/MK 0457, a potent and selective aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. Am J Transl Res. 2010, 2:296 308. 106. Arlot Bonnemains Y, Baldini E, Martin B, et al. Effects of the aurora kinase inhibitor VX 680 on anaplastic thyroid cancer derived cell lines. Endocrine Related Cancer. 2008, 15:559 68. 107. Pan C, Yan M, Yao J, et al. Aurora kinase small molecule inhibitor destroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells. Oral Oncology. 2008, 44:639 45. Green et al. Page 19 Expert Opin Drug Discov. Author manuscript, available in PMC 2012 March 1.
NIH PA Author Manuscript NIH PA Author Manuscript NIH PA Author Manuscript 108. Cheetham GMT, Charlton PA, Golec JMC, Pollard JR. Structural basis for potent inhibition of the aurora kinases and a T315I multi drug resistant mutant form of Abl kinase by VX 680. Cancer Lett. 2007, 251:323 9. 109. Donato NJ, Fang D, Sun H, et al. Targets and effectors of the cellular response to aurora kinase inhibitor MK 0457 in imatinib sensitive and resistant chronic myelogenous leukemia. Biochem Pharmacol. 2010, 79:688 97. 110. Shah NP, Skaggs B, Branford S, et al. The most common dasatinib resistant BCR ABL kinase domain mutations in patients with chronic myeloid leukemia are sensitive to VX 680: rationale for early combination kinase inhibitor therapy. Blood . 2006, 108 abstr 2175.
111. Huang X F, Luo S K, Xu J, et al. Aurora kinase inhibitory VX 680 increases Bax/Bcl 2 ratio and induces apoptosis in aurora A high acute myeloid leukemia. Blood. 2008, 111:2854 65. 112. Hose D, Reme T, Meissner T, et al. Inhibition of aurora kinases for tailored risk adapted treatment of multiple myeloma. Blood. 2009, 113:4331 40. 113. Fiskus W, Wang Y, Joshi R, et al. Cotreatment with vorinostat enhances activity of MK 0457 against acute and chronic myelogenous leukemia cells. Clin Cancer Res. 2008, 14: 6106 15. 114. Harrington EA, Bebbington D, Moore J, et al. VX 680, a potent and selective small molecule inhibitor of the aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004, 10:262 7. 115. Dai Y, Chen S, Venditti CA, et al. Vorinostat synergistically potentiates MK 0457 l